• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Insurers face off with state regulators

Article

Insurers must disclose new rates and justify increases that exceed certain thresholds

WASHINGTON-Government leaders are set to block double-digit premium hikes, forcing insurers to contend with rising costs and flat revenues. Under the Patient Protection and Affordable Care Act (PPACA), insurers must disclose new rates and justify increases that exceed certain thresholds.

Other California insurers are seeking higher premiums, too. Anthem Blue Cross is seeking a 9.8% average increase-just below the 10% threshold considered "unreasonable" in new regulations proposed late last year by the Department of Health and Human Services (HHS). Following the outrage last year over Anthem's rates, the company appears anxious to keep premium changes out of the spotlight.

State insurance regulators-not the federal government-retain authority for rejecting rates deemed unreasonable, but public disclosure of rate review information, according to HHS Secretary Kathleen Sebelius, will "rein in the kind of excessive and unreasonable rate increases that have made insurance unaffordable for so many families."

Rhode Island Insurance Commissioner Chris Koller agrees that insurance rate review will remain "essentially a state-based activity," and that the new program will provide "a backstop behind states" trying to tackle insurance rate hikes. A main benefit of the program, according to Koller, is that it offers a system for insurance commissioners to examine and question the assumptions underlying how a rate will affect enrollment demographics and other calculations used by insurers to set rates.

Karen Ignagni, president of America's Health Insurance Plans (AHIP), agrees that states are best suited to review premiums because of their knowledge of the local market and its affect on plan solvency.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.